An Acadia Pharmaceuticals Insider Sold Nearly Half Their Shares in the Company. What Does That Mean for Investors?
James Kihara, Principal Accounting Officer of Acadia Pharmaceuticals (NASDAQ:ACAD), disclosed the sale of 11,421 shares of common stock in an open-market transaction on June 26, 2026, according to the SEC Form 4 filing. Transaction summary Transaction value based on SEC Form 4 weighted average price ($26.08); post-transaction value based on June 26, 2026 market close…
